Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
56 hedge funds and large institutions have $216M invested in Adaptimmune Therapeutics in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
14% more funds holding
Funds holding: 49 → 56 (+7)
1.98% more ownership
Funds ownership: 9.36% → 11.33% (+2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less capital invested
Capital invested by funds: $219M → $216M (-$2.84M)
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$45.4M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$2.1M |
| 3 |
Renaissance Technologies
New York
|
+$1.51M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$985K |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$791K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.33M |
| 2 |
Millennium Management
New York
|
-$2.47M |
| 3 |
D.E. Shaw & Co
New York
|
-$295K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$220K |
| 5 |
Axa
Paris,
France
|
-$170K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OAJ
51
Ogorek Anthony Joseph
Williamsville,
New York
| $4K | – | – | – |
|
|
VWA
52
V Wealth Advisors
Overland Park,
Kansas
| $2K | +$2.61K | +500 | New |
|
53
Bank of America
Charlotte,
North Carolina
| $1K | +$700 | +134 | New |
|
54
Simplex Trading
Chicago,
Illinois
| $1K | +$1.61K | +309 | New |
|
|
PP
55
Paloma Partners
Greenwich,
Connecticut
| – | -$165K | -30,000 | Closed |
|
56
Zurich Cantonal Bank
Zurich,
Switzerland
| – | -$64K | -11,649 | Closed |
|
|
CSS
57
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$7K | -1,200 | Closed |
|
ADAP Hedge Fund Activity: Q2 2017 in Review
56 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q2 2017, worth a combined $216M — down 1.3% from $219M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ADAP positions and 3 closed out — a net gain of 7 holders — while 12 added to existing stakes and 13 trimmed.
The largest buyer was Matrix Capital Management Company, opening a new position worth an estimated $45.4M. The largest seller was Fidelity Investments, cutting an estimated $5.33M.
- 56 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q2 2017, up from 49 in Q1 2017.
- Funds reported $216M of Adaptimmune Therapeutics stock for Q2 2017, down 1.3% quarter-over-quarter.
- 10 funds opened new Adaptimmune Therapeutics positions in Q2 2017 and 3 closed out, a net change of +7 holders.
- The largest Adaptimmune Therapeutics buyer in Q2 2017 was Matrix Capital Management Company, an estimated $45.4M added.
- The largest Adaptimmune Therapeutics seller in Q2 2017 was Fidelity Investments, an estimated $5.33M sold.
Based on aggregated 13F filings for Q2 2017.